Product derived from milk substantially free of beta casein from non-human mammals and relative use
AssigneeMidia Limited
InventorPaolo Pozzilli
Life of this patent
Estimating the term…
Abstract
The present invention is related to a product derived from milk, substantially free of beta casein from non-human mammals. The invention is also related to the use of such a product especially in relation to diet, more particularly for early infancy, in the prevention of insulin-dependent diabets.
Claims76
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A dietary product, said product comprising at least one modified natural or synthetic bovine beta-casein protein or a fragment which does not contain the sequences:
- Pro-Gly-Pro-Ile-His (SEQ ID NO:1) and Pro-Gly-Pro-Ile-Pro (SEQ ID NO:2).
A method for the inhibition of the inductive effect on insulin-dependent diabetes caused by the administration of fragments of bovine beta casein, said method comprising the step of administering to newborns and infants an infant formula free of caseins which exhibits molecular mimicry with protein GLUT2.
A method for the inhibition of the inductive effect of bovine beta casein fragments on insulin-dependent diabetes in infants and newborns comprising the step of administering to newborns and infants an infant formula comprising at least one casein or fragments thereof selected from the group consisting of naturally occurring, recombinant, synthetic animal or vegetable caseins not containing the sequences:
- Pro-Gly-Pro-Ile-His (SEQ ID NO:1) and Pro-Gly-Pro-Ile-Pro (SEQ ID NO:2).
A method for the inhibition of the inductive effect of beta casein fragments on insulin-dependent diabetes in infants and newborns comprising the administration to newborns and infants a milk which does not contain casein fragments containing the sequences:
- Pro-Gly-Pro-Ile-His (SEQ ID NO:1) and Pro-Gly-Pro-Ile-Pro (SEQ ID NO:2), said casein being obtained by the following steps:
- providing a vector suitable for the expression of the casein;
- transfecting said vector in a cell selected from the group consisting of prokaryotic cell, unicellular eukaryotic cell or a cell derived from a multi cellular organism;
- and isolating and purifying said casein.
A product comprising at least one modified bovine beta-casein fragments selected from the group consisting of recombinant or synthetic casein fragment which do not contain the sequences:
- Pro-Gly-Pro-Ile-His (SEQ ID NO:1) and Pro-Gly-Pro-Ile-Pro (SEQ ID NO:2).
A product comprising at least one modified bovine beta-casein fragment selected from the group consisting of synthetic caseins which do not contain the sequences:
- Pro-Gly-Pro-Ile-His (SEQ ID NO:1) and Pro-Gly-Pro-Ile-Pro (SEQ ID NO:2).
A method for the inhibition of the molecular mimicry of protein GLUT2 comprising the step of administering to newborns and infants an immunogenic infant formula free of casein fragments which lack the sequences:
- Pro-Gly-Pro-Ile-His (SEQ ID NO:1) and Pro-Gly-Pro-Ile-Pro (SEQ ID NO:2).
A method for the prevention of insulin-dependent diabetes comprising the step of administering to newborns and infants an infant formula free of beta caseins that exhibit molecular mimicry with protein GLUT2.
Dependencies are inferred from the claim text.